Previous meta-analyses on NSCLC with PD-1 and PD-L1 inhibitors (19) demonstrated statistically significant associations between PD-1 inhibitors and increased pneumonia incidence at any level, including grades 3 and 4 (20, 21). This evidence concerns the gene CD274 and susceptibility to pneumonia measurement.